OKUR vs. VTGN, ADAG, IMAB, PYRGF, THTX, ANL, PMVP, EPIX, MURA, and TLSA
Should you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Vistagen Therapeutics (VTGN), Adagene (ADAG), I-Mab (IMAB), PyroGenesis Canada (PYRGF), Theratechnologies (THTX), Adlai Nortye (ANL), PMV Pharmaceuticals (PMVP), ESSA Pharma (EPIX), Mural Oncology (MURA), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.
OnKure Therapeutics vs.
Vistagen Therapeutics (NASDAQ:VTGN) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.
OnKure Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Vistagen Therapeutics' return on equity of -48.12% beat OnKure Therapeutics' return on equity.
Vistagen Therapeutics has higher revenue and earnings than OnKure Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vistagen Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
OnKure Therapeutics has a consensus price target of $36.00, indicating a potential upside of 559.34%. Given OnKure Therapeutics' higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Vistagen Therapeutics.
78.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 1.3% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Vistagen Therapeutics had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 1 mentions for Vistagen Therapeutics and 0 mentions for OnKure Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.01 beat OnKure Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Vistagen Therapeutics received 277 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 72.31% of users gave Vistagen Therapeutics an outperform vote.
Summary
Vistagen Therapeutics beats OnKure Therapeutics on 10 of the 18 factors compared between the two stocks.
Get OnKure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OnKure Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OKUR) was last updated on 2/22/2025 by MarketBeat.com Staff
